Ask about this productRelated genes to: CD70 antibody
- Gene:
- CD70 NIH gene
- Name:
- CD70 molecule
- Previous symbol:
- CD27LG, TNFSF7
- Synonyms:
- CD27L
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-08
- Date modifiied:
- 2016-10-05
Related products to: CD70 antibody
Related articles to: CD70 antibody
- Autoimmune diseases are heterogeneous disorders marked by immune dysregulation, loss of self-tolerance, autoantibody production, and chronic inflammation. Although immunosuppressants and biologics have improved disease control, incomplete remission, relapse after withdrawal, cumulative toxicity, and failure to restore immune homeostasis remain common. Chimeric antigen receptor T-cell (CAR-T) therapy offers a potential strategy for refractory autoimmune diseases by selectively eliminating pathogenic immune compartments and providing a theoretical pathway toward target-dependent immune remodeling and immune resetting. This review summarizes immunopathogenesis and therapeutic gaps in representative autoimmune diseases, compares CAR-T applications in malignancies and autoimmunity, and evaluates emerging response endpoints, target-selection strategies, and safety considerations in autoimmune settings. Early clinical evidence suggests rapid disease control, autoantibody reduction, and immunosuppression-free remission in selected B-cell- or autoantibody-driven diseases. However, reported remission duration and response proportions remain limited by small cohorts, short follow-up, and disease-specific heterogeneity. The central unresolved question is whether durable remission can be achieved without persistent immune deficiency. Cytokine release syndrome, infection, hypogammaglobulinemia, relapse, impaired vaccine responses, T-cell fitness, manufacturing barriers, and cost remain key challenges. Future studies should define optimal targets, standardized remission endpoints, durable remission biomarkers, long-term safety, and the role of T-cell engagers. - Source: PubMed
Publication date: 2026/08/06
Zhang MengtingZhao LianfengChen TianyuDing LuHe LingfengGuo Zhigang - Circadian rhythms regulate diverse immune processes, yet how they influence memory CD8 T cell differentiation remains unclear. Here, we show that the time of day of antigen encounter shapes CD8 T cell fate and antiviral immunity. Immunization during the active phase promotes the generation of progenitor-like memory CD8 T cells and enhances T cell-mediated protection upon viral challenge. Mechanistically, dendritic cell-intrinsic circadian clocks regulate expression of the costimulatory ligand CD70, thereby directing T cell differentiation. These findings uncover a dendritic cell-mediated circadian mechanism that governs memory T cell fate decisions and suggest that aligning immune priming with circadian time may be leveraged to optimize T cell immunity. - Source: PubMed
Publication date: 2026/07/31
Vleeshouwers Wardvan Duikeren Suzannede Graaf J FréderiqueVeerkamp Dominique M BLinger Marissa EJorritsma Sytze H TMyeni Sebenzile KKervezee LauraArens Ramon - Glioblastoma (GBM) is an aggressive brain tumor characterized by rapid growth and infiltration. New therapies are desperately needed to improve GBM patient outcomes. Intra-tumoral heterogeneity is a common driver of failure for novel GBM treatments, and many preclinical studies rely on cell lines established from the tumor core. As a result, they fail to characterize the infiltrative tumor cells, which remain post-surgery and ultimately drive tumor recurrence. - Source: PubMed
Publication date: 2026/07/10
Porter HarryMulhall KayleyShah MariaVinohar Jeffy JosephKaradimas Konstantinos-PanagiotisMistry ShaylenDeacon SimonHaque FarhanaBakker EmyrBoocock David JCoveney ClareLayfield RobertRahman RumanMcCrorie Phoebe - Precise diagnosis of primary and metastatic clear cell renal cell carcinoma (ccRCC) is an unmet clinical challenge. CD70 is a biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases. Devising immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers targeting CD70 will enable noninvasive, accurate diagnosis of ccRCC. By immunizing alpacas with the recombinant human CD70 protein, we obtained a single-domain antibody (sdAb), R8B4, with an affinity of 9.583 nM. First, by harnessing F labeling, we developed a CD70 immunoPET/CT tracer, [F]-AlF-RESCA-R8B4, and verified its diagnostic accuracy in preclinical ccRCC models. Subsequently, the more readily available [Ga]-Ga-NOTA-R8B4 was constructed using Ga labeling, and its targeting performance was also validated. Compared with [F]-AlF-RESCA-R8B4, [Ga]-Ga-NOTA-R8B4 showed lower renal accumulation. Following this, we conducted a preliminary investigator-initiated clinical trial that demonstrated that [F]-AlF-RESCA-R8B4 clearly visualized CD70-positive metastatic lesions in ccRCC patients. With improved pharmacokinetics and reduced kidney accumulation, [Ga]-Ga-NOTA-R8B4 immunoPET/CT shows preliminary, yet promising, value for accurately detecting primary lesions in ccRCC patients. Future studies are warranted to explore the diagnostic and predictive value of the CD70-targeted immunoPET/CT imaging approaches in ccRCC patients. - Source: PubMed
Publication date: 2026/02/20
Zhang YouWu QianyunAn ShuxianXu DongshengJia WenzhiHu ZhoumiWang ChengHuang GangZhang JinLiu JianjunWei Weijun - Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated FL patients with extended follow-up (>11 years), comparing relapsed and relapse-free cases. Transcriptomic profiling revealed enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8⁺ and CD4⁺ T follicular helper (TFH) cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70⁺ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current CAR-T approaches, we engineered dual CD19-CD70 chimeric antigen receptor (CAR) T cells by co-transducing the CD19-CAR-T ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR-T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR-T treatment achieved superior disease control compared to monotargeted CAR-T cells, inducing complete tumor clearance in spleen and bone marrow. Collectively, these findings provide strong preclinical rationale for the clinical development of CD19-CD70 dual CAR-T therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas. - Source: PubMed
Publication date: 2026/07/22
Araujo-Ayala FerranRos MariaAlexandru RalucaMateos-Jaimez JudithRodríguez-Garcia AlbaGiménez-Alejandre MartaVillalba-Esparza MaríaMozas PabloColell GuillemColell SalutBachiller MireiaNadeu FerranRivero AndreaGiro AriadnaHodson Daniel JPoddar SoumyaLópez-Guillermo ArmandoColomer DolorsMaiques-Diaz AlbaMartín-Subero José-IgnacioBeà SilviaMagnano LauraSmith Mitchell ReedUrbano-Ispizua ÁlvaroDelgado JulioJuan ManelCampo ElíasDe Andrea Carlos EGuedan SoniaPérez-Galán Patricia